Point-of-care urine tenofovir test predicts future HIV preexposure prophylaxis discontinuation among young users. Read more about Point-of-care urine tenofovir test predicts future HIV preexposure prophylaxis discontinuation among young users.
Distinct anal microbiome is correlated with anal cancer precursors in MSM with HIV. Read more about Distinct anal microbiome is correlated with anal cancer precursors in MSM with HIV.
An agricultural livelihood intervention is associated with reduced HIV stigma among people with HIV. Read more about An agricultural livelihood intervention is associated with reduced HIV stigma among people with HIV.
Impact of a livelihood intervention on gender roles and relationship power among people with HIV. Read more about Impact of a livelihood intervention on gender roles and relationship power among people with HIV.
Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. Read more about Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use.
Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size. Read more about Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size.
Controlled attenuation parameter accurately detects liver steatosis in people with HIV. Read more about Controlled attenuation parameter accurately detects liver steatosis in people with HIV.
Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. Read more about Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection.
Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy. Read more about Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV. Read more about SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV.
